Hematologic Malignancies
Conditions
Keywords
Leukemia, Graft vs. Host Disease, Hematopoietic Stem Cell Transplant, Bone Marrow Transplant, Myelodysplasia
Brief summary
The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
Detailed description
Graft-vs.-Host Disease (GVHD) is one of the major limitations of allogeneic hematopoietic stem cell transplants (HSCT). This complication is major cause of morbidity and mortality and is thought to be initiated by activation of donor T-cells through recognition of foreign cells resident in the transplant recipient. Acute GVHD is associated with damage to the liver, skin, gastrointestinal tract and mucosa. Moderate to severe GVHD Grades II-IV occurs in 30-50% of matched related HSCTs and 50-70% of unrelated donor recipients. Severe GHVD requires intense immunosuppression involving steroids and additional agents to get it under control, and patients may develop severe infections as a result of such immunosuppression. An agent or cell therapy that could reduce the incidence and/or severity of GVHD without increasing relapse or infectious risk in HSCT patients would provide substantial benefits.
Interventions
BIOLOGICALMultiStem®
Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
Sponsors
Cato Research
Healios K.K.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients of either sex aged 18-65 years of age * Diagnosis of acute myeloid or lymphoblastic leukemia (second or subsequent remission, if not in remission, then \<20% bone marrow blasts), chronic myelogenous leukemia resistant to or intolerant of tyrosine kinase inhibitor therapy (accelerated phase, first chronic phase with TKI resistance, or second chronic phase), or myelodysplastic syndrome (intermediate/high or high risk by International Prognostic Scoring System (IPSS), lower risk by IPSS with patient having progressed after prior therapy. Complete remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment and \<5% blasts in the marrow within 28 days of enrollment. * Life expectancy of at least 100 days * Patients scheduled for allogeneic bone marrow transplant or peripheral blood stem cell transplant (PBST) procedure * Family-related or unrelated donors * HLA matching should either be matched related or matched unrelated donors, 6/6 match or 5/6 single allelic mismatch, with provision that the DRB1 is molecularly matched * Performance status (ECOG ≤2) * Signed informed consent
Exclusion criteria
* Active infection * Known allergies to bovine or porcine products * Renal function: Serum creatinine \>2 mg/dL or creatinine clearance ≤50 mL/min * Hepatic function: Screening ALT or AST ≥3x than the upper limit of normal for the laboratory OR total bilirubin ≥2.0 mg/dL (Exception: acceptable if patient is identified with pre-existing condition e.g., Gilbert's disease that will contribute to baseline elevations of bilirubin) * Pulmonary function: FEV1, FVC, DLCO ≤50% predicted * Cardiac function: left ventricular ejection fraction ≤50% * Patient received an investigational agent within 30 days prior to transplant * The patient is pregnant, has a positive serum BhCG, or is lactating * Patient on corticosteroids at a dose \>0.25 mg/kg/day * Planned non-myeloablative transplant * Planned cord blood transplant * Prior allogeneic myeloablative HSCT * HIV seropositive, HTLV seropositive, hepatitis B or C seropositive, varicella virus active infection, or syphilis active infection * Other serious medical or psychiatric illness that, in the investigator's opinion, would not permit the patient to be managed according to the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum tolerated dose | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| incidence of grade III/IV GVHD | 100 days |
Countries
Belgium, United States
Outcome results
None listed